TXNDC5 and glioblastoma: In addition, TXNDC5 levels were elevated in recurring LGG (Figure 5M) and all grade patients (Figure 5O) whereas there was no significant difference in TXNDC5 expression between disease free and recurred groups in GBM patients (Figure 5N).